ASX:OPT

OPTHEA LIMITED

OPTHEA LIMITED has not announced any capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise

< $50k

Investors Interested in Next Raise

< 10

How Fresh Equities Works

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

2. View Terms

View the full term sheet for the capital raise.

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

Company Overview

Opthea Limited (OPT, formerly Circadian Technologies Limited) is a biologics drug developer focusing on ophthalmic disease therapies. Opthea's lead molecule is OPT-302 for the treatment of �back of the eye' disease such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT-302 is a soluble form of VEGFR-3 that acts a VEGF-C/VEGF-D 'trap'. Former Names Circadian Technologies Limited (CIR), 11/12/2015

Type

Listed Company

GICS Sub-industry

Biotechnology

Head Office

Unit 4/650 Chapel St, South Yarra VIC 3141, Australia

Website

www.opthea.com

Biotechnology

Health Care

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.